Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic Repurposing of Biguanides in Cancer

Trends in cancer(2021)10.1016/j.trecan.2021.03.001Source: DataRank Database

Therapeutic Repurposing of Biguanides in Cancer is a research paper published in Trends in cancer (2021). On theSindex it has a DataRank of 0. It has been cited 70 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access70 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 4.25)OA: greenTopics (52)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Kenneth D. Swanson,Bin Zheng ORCID,Hongyun Zhao ORCID

Live enrichment

PubMed:33865798 PMC:PMC8295194 OpenAlex:https://openalex.org/W3152542406

National Institutes of Health

Grant: R00 CA133245

National Institutes of Health

Grant: R01 CA166717

National Institutes of Health

Grant: R21 CA227588

Melanoma Research Alliance

FWCI

4.25

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8295194

publisherhttps://api.elsevier.com/content/article/PII:S2405803321000649?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2405803321000649?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.trecan.2021.03.001

Fields of Study

Metabolism, Diabetes, and CancerPancreatic function and diabetesCancer, Hypoxia, and MetabolismAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiguanidesCell Line, TumorClinical Trials as TopicDisease Models, AnimalDrug RepositioningDrug SynergismHumansImmune Checkpoint InhibitorsNeoplasmsOxidative PhosphorylationProtein Kinase InhibitorsTumor MicroenvironmentXenograft Model Antitumor Assays

MeSH Terms

Immune Checkpoint InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiguanidesClinical Trials as TopicDisease Models, AnimalDrug SynergismHumansNeoplasmsOxidative PhosphorylationXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsDrug RepositioningTumor Microenvironment

Keywords

PhenforminBiguanideMedicineMetforminPharmacologyCancerRepurposingAMPKCombination therapyOvarian cancerDiabetes mellitusInternal medicineProtein kinase ABiologyEndocrinologyKinaseCancer ImmunotherapyCancer Cell MetabolismImmunometabolism

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 3 of Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas

10.6084/m9.figshare.19218687.v1figshare

Additional file 3 of Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas

10.6084/m9.figshare.19218687figshare

Additional file 2 of Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas

10.6084/m9.figshare.19218681.v1figshare

Additional file 2 of Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas

10.6084/m9.figshare.19218681figshare

Additional file 1 of Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas

10.6084/m9.figshare.19218675.v1figshare

Additional file 1 of Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas

10.6084/m9.figshare.19218675figshare

Therapeutic Repurposing of Biguanides in Cancer

FAIR Checklist

Authors (3)

Funding (4 grants)

Impact

Open Access

Topics

Linked Datasets (6)

Annotations (Europe PMC)